ICU sedation, delirium & recovery
Hemodynamic impact of dexmedetomidine in critically ill patients with and without cirrhosis: A retrospective cohort study
Authors' conclusion
Dexmedetomidine use was associated with higher rates of bradycardia, severe bradycardia, and hypotension in patients with cirrhosis.
Study context
- Population
- Adult medical or surgical ICU patients receiving ≥2 h of dexmedetomidine infusion, multiple Cleveland Clinic hospitals, November 2018–December 2021
- Participants
- 157 participants
- Exposure
- Dexmedetomidine in patients with vs without cirrhosis
- Cirrhosisn = 37
- Without cirrhosisn = 120reference
- Outcome
- Incidence of bradycardia during dexmedetomidine infusion
Methodological detailsobservational, multicentre, multivariable logistic regression
- Observational
- Multicentre
- Multivariable logistic regression
Main finding
As reported in the abstract
Bradycardia during dexmedetomidine infusion
Cirrhosis vs Without cirrhosisEstimate (95% CI)
Bradycardia during dexmedetomidine infusion
RR 1.9(1.1–3.2)
After adjustment
adjusted OR 2.24(0.96–5.21)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | aOR (95% CI) | |
|---|---|---|
| Bradycardia during dexmedetomidine infusion (multivariable adjusted)Cirrhosis vs No cirrhosis | 2.24 (0.96–5.21) | |
| Hypotension (multivariable adjusted) · first 24 hCirrhosis vs No cirrhosis | 2.36 (0.99–5.63) | |
| 0.20.5125Adjusted odds ratio (log scale) |
Safety
| Outcome | Adjusted OR (95% CI) | |
|---|---|---|
| Hypotension · first 24 h | 2.36 (0.99–5.63) | |
| 0.20.5125Adjusted odds ratio (log scale) |
Original publication
Hemodynamic impact of dexmedetomidine in critically ill patients with and without cirrhosis: A retrospective cohort study. J Crit Care. Published 12 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →